New Findings from Beth Israel Deaconess Medical Center in Lupus Provides New Insights (The Pp2a Regulatory Subunit Ppp2r2a Controls Nad Plus Biosynthesis To Regulate T Cell Subset Differentiation In Systemic Autoimmunity).

A recent study conducted at Beth Israel Deaconess Medical Center in Boston, Massachusetts, has found that the protein phosphatase 2A (PP2A) regulatory subunit PPP2R2A plays a role in regulating the immune response in lupus-prone mice. The deficiency of PPP2R2A promotes NAD+ biosynthesis, which inhibits the production of proinflammatory cytokines and promotes the differentiation of regulatory T cells. The study suggests that targeting NAD+ biosynthesis could be a potential therapeutic strategy for lupus. This research was supported by the National Institutes of Health (NIH) in the United States. [Extracted from the article]